PMPRB issues a Notice of Hearing for allegations of excessive pricing of PROCYSBI
The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling or has sold PROCYSBI (cysteamine bitartrate) in any market in Canada at a price that, in the Board's opinion, is or was excessive; and if so, what order, if any, should be made to remedy the excessive pricing.
News Release; Notice of Hearing; Statement of Allegations of Board Staff
Under reserve: Appeal from judicial review quashing PMPRB decision on jurisdiction over DIFFERIN
On January 17, 2019, the Federal Court of Appeal heard the Attorney General of Canada’s appeal from a judicial review that quashed a Board decision that it has jurisdiction over Galderma’s DIFFERIN (0.1% adapalene). Our report on the Federal Court decision, 2017 FC 1023, is found here. Innovative Medicines Canada intervened in the appeal. The Federal Court of Appeal reserved judgment.
Related Publications & Articles
-
Agile licensing amendments registered
Following consultation starting in 2022, on November 29, 2024, Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) were registered.Read More -
2024 highlights in Canadian life sciences IP and regulatory law
In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
Health Canada proposes to amend the Food and Drug Regulations and Medical Devices Regulations to address shortages
On December 28, 2024, Health Canada published proposed amendments to the Food and Drug Regulations and Medical Devices Regulations to address therapeutic product shortages (see our previous article re...Read More